Gaois

Cóip statach de shonraí a easpórtáiltear ó IATE ó am go chéile atá sa chnuasach seo. Níor cheart glacadh leis gurb ionann i gcónaí an t-eolas a thugtar faoi iontráil anseo agus a bhfuil sa leagan reatha den iontráil ar IATE. Is féidir an leagan reatha sin a cheadú ach cliceáil ar an nasc atá ar thaobh na láimhe deise ag barr gach iontrála. Breis eolais »

262 toradh

  1. INDUSTRY|chemistry|chemical compound
    1,3,5-trínítrea-1,3,5-trí-aisín Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    RDX Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    cioglóinít Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    heicsigin Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Cyclonit | Hexogen | Cyclotrimethylen-trinitramin | RDX | Trimethylentrinitramin | Sprengstoff
    de
    1,3,5-trinitroperhydro-1,3,5-triazine | RDX | hexogen | Royal Demolition eXplosive | Research Department eXplosive | T4 | cyclotrimethylenetrinitramine | cyclonite
    en
    Sainmhíniú powerful explosive in the form of a hard, white crystalline solid that is insoluble in water Tagairt COM-Terminology Coordination, based on:"RDX". Encyclopaedia Britannica, http://www.britannica.com/technology/RDX [29.4.2016]
    RDX | cyclotrimethylene-trinitramine | hexogene | cyclonite
    fr
  2. SOCIAL QUESTIONS|health|pharmaceutical industry
    (1R)-1,2-ainhidrea-4-C-(1E,3E)-4-[(1S,2S,3E,5R,6R,9R)-5-(1-carbocsalátai-4-cioglaiheiptilpipioraisin-2-il)-6,9-déhiodrocsa-2,6-démheitiol-11-ocsó-ocsaiciogladóideic-3-éin-1-il]peinti-1,3-dé-éin-1-il-3,5-dédí-ocsa-1-[(2R,3S)-3-hiodrocsaipeintin-2-il]-D-eiritripeinteatól Tagairt Fiontar, DCU
    ga
    (1R)-1,2-anhydro-4-C-{(1E,3E)-4-[(1S,2S,3E,5R,6R,9R)-5-(1-carboxylato-4-cycloheptylpiperazin-2-yl)-6,9-dihydroxy-2,6-dimethyl-11-oxooxacyclododec-3-en-1-yl]penta-1,3-dien-1-yl}-3,5-dideoxy-1-[(2R,3S)-3-hydroxypentan-2-yl]-D-erythropentitol
    en
  3. SOCIAL QUESTIONS|health|pharmaceutical industry
    (1S)-1,5:7,10-dé-ainhidri-12,13-bis-O-[treas-bhúitil(démheitil)silil]-2,3,4,6,8,11-heicsead-ocsai-1-2- [(2S,5S)-5-(3-hiodrocsapróipil)-3-meitilidéinteitrihidreafúráin-2-il]eitil-3-meitil-9-O- meitil-4-meitilidéin-8-[(feiniolsulfáinil)meitiol-D-arabanó-D-altra-trídeiceatól Tagairt Fiontar, DCU
    ga
    (1S)-1,5:7,10-dianhydro-12,13-bis-O-[tert-butyl(dimethyl)silyl]-2,3,4,6,8,11-hexadeoxy-1-{2-[(2S,5S)-5-(3-hydroxypropyl)-3-methylidenetetrahydrofuran-2-yl]ethyl}-3-methyl-9-O-methyl-4-methylidene-8-[(phenylsulfonyl)methyl]-D-arabino-D-altro-tridecitol
    en
  4. SOCIAL QUESTIONS|health|pharmaceutical industry
    (3-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trífhluaraimeitil)feinil]eatocsa}-3-(2-fluaraifeinil)morfóilin-4-il]meitil}-5-ocsói-2,5-déhidri-1H-1,2,4-trí-asóil-1-il)aigéad fosfónach --1-dí-ocsa-1-(meitiolaimín)-D-glúicíotól Tagairt Fiontar, DCU
    ga
    (3-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(2-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-2,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid -- 1-deoxy-1-(methylamino)-D-glucitol (1:2)
    en